Tech Pivots to Cloud Mega-Deals as AI Momentum Spills Into Biopharma
I'm LongbridgeAI, I can summarize articles.Akamai's $1.8 billion cloud infrastructure contract and Jupiter Neurosciences' $100 million licensing pact highlight a landscape increasingly driven by high-conviction dealmaking and AI-integrated capital expenditures.
Akamai Technologies (AKAM.US) is aggressively accelerating its pivot from legacy content delivery, securing a $1.8 billion cloud contract that signals a broader infrastructure shift. The Cambridge-based firm expects cloud services to jump at least 50% in 2026, a growth mandate bolstered by its recent $205 million acquisition of AI-security startup LayerX.
That AI momentum is rapidly spilling into life sciences. Generate Biomedicines Inc. (GENB.US), backed by Nvidia Corp., closed the first quarter of 2026 with $516 million in cash as it pushes its AI-designed monoclonal antibodies through late-stage clinical trials. The broader tech and growth proxy, mirrored by assets like MQQQ.US, continues to digest these massive, algorithm-driven capital expenditures.
In the biopharma space, dealmaking remains brisk. Jupiter Neurosciences Inc. (JUNS.US) inked a licensing pact worth up to $100 million for US rights to a next-generation MDMA therapy, diversifying its pipeline well beyond its Phase 2a Parkinson’s asset. Meanwhile, mega-cap players like Novartis AG (NVS.US) continue to anchor the global healthcare landscape, while life-sciences supplier Avantor Inc. (AVTR.US) reported first-quarter revenue of $1.58 billion, beating analyst estimates on improved execution in its biosciences unit.
Traditional infrastructure and yield plays are heavily tapping debt markets. Energy Transfer LP (ET.US) priced $1.75 billion in junior subordinated notes to fund capital projects, including the fully-subscribed expansion of its Nederland export terminal. Income-focused vehicles like the PIMCO Corporate & Income Opportunity Fund (PTY.US) are navigating this high-yield issuance environment to lock in capital.
In the materials sector, SES AI Corp. (SES.US) is facing capital market headwinds. Despite a recent inclusion in the Russell 3000 index, the lithium-metal battery maker received a NYSE non-compliance notice after its stock price languished below minimum bid requirements, overshadowing its 47% sequential revenue growth in the first quarter of 2026. Regional financial entities, including Phoenix Asia Holdings Limited (PHOE.US), round out a quarter marked by stark divergences between AI-fueled tech valuations and legacy operational restructuring.